Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | PTCL arising as a PTLD: the efficacy of pralatrexate

Owen O'Connor • 19 Jun 2019
ICML 2019
Lymphoma Non-Hodgkin Lymphoma T-Cell Lymphoma Pralatrexate

Owen O’Connor, MD, PhD, Columbia University Medical Center, New York, NY, discusses peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder (PTLD) and the efficacy of pralatrexate for the treatment of this condition. To read the specific case report mentioned please use this link: https://www.ncbi.nlm.nih.gov/pubmed/31184235

More from Owen O'Connor

Immunoepigenetic platforms for PTCL treatment 6:47
Immunoepigenetic platforms for PTCL treatment
Owen O'Connor • 2 Jul 2019
The role of epigenetic modulators in the pathogenesis of lymphomas 9:20
The role of epigenetic modulators in the pathogenesis of lymphomas
Anas Younes et al. • 18 Sep 2017
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al. • 8 Sep 2017
TGR-1202, novel PI3K delta inhibitor, for hematological malignancies 5:45
TGR-1202, novel PI3K delta inhibitor, for hematological malignancies
Owen O'Connor • 3 Oct 2015

Related Videos

Glofitamab and obinutuzumab as first-line therapy for patients with high-tumor burden FL 2:11
Glofitamab and obinutuzumab as first-line therapy for patients with high-tumor burden FL
Reid Merryman • 8 Dec 2025
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals